Allspring Global Investments
ACRS icon

Allspring Global Investments’s Aclaris Therapeutics ACRS Stock Holding History

Allspring Global Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65,307
Closed -$1.03M – 2764
2022
Q4 		$1.03M Sell
65,307
-829
-1% -$13.3K ﹤0.01% 1423
2022
Q3 		$1.04M Buy
+66,136
New +$1.04M ﹤0.01% 1420
2022
Q2 		– Sell
-7,726
Closed -$133K – 2678
2022
Q1 		$133K Sell
7,726
-833
-10% -$11.4K ﹤0.01% 2688
2021
Q4 		$124K Buy
+8,559
New +$130K ﹤0.01% 2740

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Allspring Global Investments's ACRS Position: Q1 2023 in Review

Allspring Global Investments sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 65,307 shares — an estimated $1.03M sold.

Allspring Global Investments first reported a position in ACRS in Q4 2021 and held it in 4 quarters. The position peaked at $1.04M in Q3 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

  • Allspring Global Investments reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Allspring Global Investments sold 65,307 Aclaris Therapeutics shares in Q1 2023, an estimated $1.03M.
  • Allspring Global Investments first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 4 quarters.
  • Allspring Global Investments's Aclaris Therapeutics position peaked at $1.04M in Q3 2022.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Allspring Global Investments's 13F filing for Q1 2023, filed 13 Apr 2023.